Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Sell

C

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Pharmaceutical Preparations

https://www.corbuspharma.com

Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune systems. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus' internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells.

500 RIVER RIDGE DRIVE
NORWOOD, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/24/2014

Market Cap

646,516,552

Shares Outstanding

4,420,000

Weighted SO

4,423,683

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

LIFE --.--%

TRVI --.--%

CUE --.--%

ANTX --.--%

BCAB --.--%

KOD --.--%

GLMD --.--%

AFMD --.--%

MREO --.--%

Beta

2.5930

Last Div

0.0000

Range

3.033-61.9

Chg

-1.2300

Avg Vol

295724

Mkt Cap

646516552

Exch

NASDAQ

Country

US

Phone

617 963 0100

DCF Diff

55.8002

DCF

-1.6102

Div Yield

0.0000

P/S

478.9778

EV Multiple

-16.1414

P/FV

4.7262

Div Yield %

0.0000

P/E

-16.9668

PEG

-0.7376

Payout

0.0000

Current Ratio

6.1848

Quick Ratio

6.1848

Cash Ratio

0.9996

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

644.4385

CCC

-644.4385

Gross Margin

0.5166

Op Margin

-29.7840

Pretax Margin

-25.9082

Net Margin

-25.9082

Eff Tax Rate

-0.0237

ROA

-0.2301

ROE

-0.6479

ROCE

-0.3141

NI/EBT

1.0000

EBT/EBIT

0.8699

EBIT/Rev

-29.7840

Debt Ratio

0.0974

D/E

0.1179

LT Debt/Cap

0.0192

Total Debt/Cap

0.1054

Int Coverage

-62.6833

CF/Debt

-2.0340

Equity Multi

1.2106

Rec Turnover

0.0000

Pay Turnover

0.5664

Inv Turnover

0.0000

FA Turnover

0.4111

Asset Turnover

0.0089

OCF/Share

-2.7228

FCF/Share

-2.7228

Cash/Share

13.3273

OCF/Sales

-22.2963

FCF/OCF

1.0000

CF Coverage

-2.0340

ST Coverage

-2.4388

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

4.7262

P/B

4.7262

P/S

478.9778

P/E

-16.9668

P/FCF

-21.4824

P/OCF

-19.7153

P/CF

-19.7153

PEG

-0.7376

P/S

478.9778

EV Multiple

-16.1414

P/FV

4.7262

DPS

0.0000

Latest Headlines (EST)

No Headlines Found

Revenue Product Segmentation